A Chinese randomized trial found a trend toward clinical improvement with plasma therapy (51.9% vs 43.1%) but failed to reach statistical significance ( P = 0.26), presumably because of underpowering as the study was terminated early due to a decline in COVID-19 cases in China[ 120 ].
← all excerpts
Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19.
1
0.2600
0.2600